| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.TRRE.2020.100573 |
| P698 | PubMed publication ID | 33002671 |
| P2093 | author name string | Ileana Constantinescu | |
| Ioanel Sinescu | |||
| Gener Ismail | |||
| Bogdan Marian Sorohan | |||
| Cătălin Baston | |||
| Nicolae Leca | |||
| Dorina Tacu | |||
| Bogdan Obrișcă | |||
| P2860 | cites work | The angiotensin II AT1 receptor structure-activity correlations in the light of rhodopsin structure | Q28297667 |
| Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor | Q30747560 | ||
| Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity | Q33748680 | ||
| Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients | Q33765684 | ||
| Localization and function of angiotensin AT1 receptors | Q33839720 | ||
| Interplay between miR-155, AT1R A1166C polymorphism, and AT1R expression in young untreated hypertensives. | Q34145150 | ||
| Increase of angiotensin II type 1 receptor auto-antibodies in Huntington's disease | Q34581918 | ||
| Diagnosis and management of antibody-mediated rejection: current status and novel approaches | Q34841849 | ||
| Complement C4d in graft capillaries -- the missing link in the recognition of humoral alloreactivity | Q35142594 | ||
| Investigation of Serum Angiotensin II Type 1 Receptor Antibodies at the Time of Renal Allograft Rejection | Q35332030 | ||
| Identification of the target self-antigens in reperfusion injury | Q36227933 | ||
| IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury | Q36417907 | ||
| Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system | Q36548154 | ||
| Non-HLA antibodies post-transplantation: clinical relevance and treatment in solid organ transplantation | Q37323165 | ||
| Angiotensin II type-1 receptor (AT1R) regulates expansion, differentiation, and functional capacity of antigen-specific CD8(+) T cells | Q37366984 | ||
| Chronic humoral rejection of human kidney allografts associates with broad autoantibody responses | Q37394650 | ||
| Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis | Q37689681 | ||
| T cell-mediated rejection of kidney transplants: a personal viewpoint. | Q37719749 | ||
| Acute vascular rejection after renal transplantation and isolated v-lesion | Q38022714 | ||
| Antibody-mediated vascular rejection of kidney allografts: a population-based study | Q38062614 | ||
| Non-HLA antibodies in solid organ transplantation: recent concepts and clinical relevance | Q38120396 | ||
| Non-HLA antibodies against endothelial targets bridging allo- and autoimmunity | Q38836521 | ||
| Angiotensin II type 1 receptor antibodies in childhood kidney transplantation | Q38859507 | ||
| The importance of non-HLA antibodies in transplantation | Q38877375 | ||
| The Emerging Importance of Non-HLA Autoantibodies in Kidney Transplant Complications | Q38995184 | ||
| Not All Antibodies Are Created Equal: Factors That Influence Antibody Mediated Rejection | Q39217968 | ||
| AT1 receptor signaling pathways in the cardiovascular system | Q39319793 | ||
| A stepwise breakdown of B-cell tolerance occurs within renal allografts during chronic rejection | Q39470034 | ||
| Anti-Angiotensin II Type 1 Receptor and Anti-Endothelial Cell Antibodies: A Cross-Sectional Analysis of Pathological Findings in Allograft Biopsies | Q39737548 | ||
| Histopathologic changes in anti-angiotensin II type 1 receptor antibody-positive kidney transplant recipients with acute rejection and no donor specific HLA antibodies | Q40296432 | ||
| Genetic variants of angiotensin II receptors and cardiovascular risk in hypertension. | Q40567771 | ||
| Autoantibodies Toward the Angiotensin 2 Type 1 Receptor: A Novel Autoantibody in Alzheimer's Disease | Q41325907 | ||
| Angiotensin II receptors in endothelial cells | Q41623699 | ||
| Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss | Q43817587 | ||
| Association of anti-human leukocyte antigen and anti-angiotensin II type 1 receptor antibodies with liver allograft fibrosis after immunosuppression withdrawal | Q44401216 | ||
| Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection | Q45259438 | ||
| Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions | Q45342440 | ||
| Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation | Q45627897 | ||
| Angiotensin II Type 1 receptor antibodies are associated with inflammatory cytokines and poor clinical outcomes in pediatric kidney transplantation | Q46409439 | ||
| Angiotensin II type 1 receptor expression on human leukocyte subsets: a flow cytometric and RT-PCR study. | Q46986151 | ||
| C4d-negative antibody-mediated rejection with high anti-angiotensin II type I receptor antibodies in absence of donor-specific antibodies | Q47571875 | ||
| Angiotensin II type-1 receptor antibody (AT1Rab) associated humoral rejection and the effect of peri operative plasma exchange and candesartan. | Q47608906 | ||
| Renal ischemia and transplantation predispose to vascular constriction mediated by angiotensin II type 1 receptor-activating antibodies | Q47630949 | ||
| Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies | Q47789001 | ||
| The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. | Q48112113 | ||
| Is pre-transplant sensitization against angiotensin II type 1 receptor still a risk factor of graft and patient outcome in kidney transplantation in the anti-HLA Luminex era? A retrospective study. | Q48160896 | ||
| Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis | Q48577521 | ||
| Deleterious Effect of Anti-Angiotensin II Type 1 Receptor Antibodies Detected Pretransplant on Kidney Graft Outcomes is Both Proper and Synergistic WITH DONOR-SPECIFIC ANTI-HLA ANTIBODIES. | Q49936573 | ||
| Association of angiotensin II type 1 receptor antibodies with graft histology, function and survival in paediatric renal transplant recipients | Q49998785 | ||
| Pre-transplant AT1R antibodies correlate with early allograft rejection. | Q50022460 | ||
| Pre-transplant screening for non-HLA antibodies: Who should be Tested? | Q50049252 | ||
| Assessing the potential of angiotensin II type 1 receptor and donor specific anti-endothelial cell antibodies to predict long-term kidney graft outcome. | Q50752503 | ||
| Sequential analysis of donor-specific antibodies and pathological findings in acute antibody-mediated rejection in a rat renal transplantation model. | Q51043732 | ||
| Is parvovirus B19 the cause for autoimmunity against the angiotensin II type receptor? | Q52928690 | ||
| Anti-angiotensin type 1 receptor antibodies associated with antibody-mediated rejection in patients without preformed HLA-donor-specific antibody. | Q53245556 | ||
| Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients. | Q53504304 | ||
| Clinical implications of angiotensin II type 1 receptor antibodies in antibody-mediated rejection without detectable donor-specific HLA antibodies after renal transplantation. | Q53536001 | ||
| A 2018 Reference Guide to the Banff Classification of Renal Allograft Pathology | Q57175415 | ||
| Vascular Receptor Autoantibodies in Pulmonary Arterial Hypertension Associated with Systemic Sclerosis | Q57823948 | ||
| Pretransplant angiotensin ii type 1-receptor antibodies point to an increase in renal graft sub-intimal fibrosis in living- donor kidney transplant recipients | Q58566327 | ||
| Development and Validation of a Multiplex Non-HLA Antibody Assay for the Screening of Kidney Transplant Recipients | Q60946989 | ||
| Cytokine Profiles Associated With Angiotensin II Type 1 Receptor Antibodies. | Q64939685 | ||
| Clinical Impact of Pre-transplant Antibodies Against Angiotensin II Type I Receptor and Major Histocompatibility Complex Class I-Related Chain A in Kidney Transplant Patients. | Q64956036 | ||
| Intrarenal localization of angiotensin II type 1 receptor mRNA in the rat | Q72791694 | ||
| Tissue-specific expression of type 1 angiotensin II receptor subtypes. An in situ hybridization study | Q72803654 | ||
| Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension | Q74126541 | ||
| Photolabeling identifies position 172 of the human AT(1) receptor as a ligand contact point: receptor-bound angiotensin II adopts an extended structure | Q74138374 | ||
| Increased expression of angiotensin II type 1 receptor (AGTR1) in heart transplant recipients with recurrent rejection | Q79347904 | ||
| Incidence and prediction of early antibody-mediated rejection due to non-human leukocyte antigen-antibodies | Q81448662 | ||
| Cytokine gene expression in kidney allograft biopsies after donor brain death and ischemia-reperfusion injury using in situ reverse-transcription polymerase chain reaction analysis | Q81591077 | ||
| Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies | Q81706493 | ||
| Anti-Angiotensin Type 1 Receptor Antibodies Associated With Antibody Mediated Rejection in Donor HLA Antibody Negative Patients | Q82213207 | ||
| Angiotensin type-1 receptor A1166C gene polymorphism correlates with oxidative stress levels in human heart failure | Q83228715 | ||
| The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes | Q88040407 | ||
| Circulating angiotensin type II receptor: Possible marker for antibody mediated rejection after renal transplantation? | Q88312145 | ||
| Prevalence of Antibody against Angiotensin II Type 1 Receptor (AT1R) Among Thai Kidney Transplant Patients | Q89029587 | ||
| Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies | Q89275357 | ||
| Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients | Q90038238 | ||
| Preformed Angiotensin II Type-1 Receptor Antibodies Are Associated With Rejection After Kidney Transplantation: A Single-Center, Cohort Study | Q90704817 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 100573 | |
| P577 | publication date | 2020-09-25 | |
| P1433 | published in | Transplantation Reviews | Q15749559 |
| P1476 | title | Angiotensin II type 1 receptor antibodies in kidney transplantation: An evidence-based comprehensive review | |
| P478 | volume | 34 |
Search more.